Aarthi Chary

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials
    Aarthi Chary
    VA Palo Alto Health Care System, Palo Alto, CA 94304, USA
    Rev Recent Clin Trials 5:158-73. 2010
  2. pmc Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients
    Aarthi Chary
    AIDS Research Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA
    J Infect Dis 202:889-93. 2010
  3. doi request reprint Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection
    Aarthi Chary
    AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California, USA
    J Med Virol 84:431-7. 2012
  4. doi request reprint Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients
    Mark A Winters
    AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California 94304, USA
    J Med Virol 82:791-8. 2010
  5. doi request reprint Interferon combination therapy for HIV/hepatitis C virus coinfection
    Aarthi Chary
    VA Palo Alto Health Care System, Palo Alto, CA, USA
    Immunotherapy 3:1087-102. 2011
  6. pmc Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients
    Lauren E Kushner
    Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America
    PLoS ONE 8:e60387. 2013

Collaborators

  • Mark Holodniy
  • David M Asmuth
  • Mark A Winters
  • Lauren E Kushner
  • Michael A Polis
  • Laura C Lazzeroni
  • Shyam Kottilil
  • Anu Osinusi
  • Aaron M Wendelboe
  • Robert Eison

Detail Information

Publications6

  1. ncbi request reprint Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials
    Aarthi Chary
    VA Palo Alto Health Care System, Palo Alto, CA 94304, USA
    Rev Recent Clin Trials 5:158-73. 2010
    ..This review outlines the advances and the challenges in the development of these HCV PIs as effective HCV antiviral agents and their role in clinical practice...
  2. pmc Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients
    Aarthi Chary
    AIDS Research Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA
    J Infect Dis 202:889-93. 2010
    ..The effect of prior interferon-ribavirin treatment on HCV NS3 will likely not impact HCV PI efficacy in HIV-coinfected patients receiving ART...
  3. doi request reprint Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection
    Aarthi Chary
    AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California, USA
    J Med Virol 84:431-7. 2012
    ..Differences in PBMC HCV viral load based on HIV-coinfection status and the significance of greater copy number in B-cells requires further study...
  4. doi request reprint Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients
    Mark A Winters
    AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California 94304, USA
    J Med Virol 82:791-8. 2010
    ..These results suggest ARV treatment for HIV would not affect the efficacy of HCV PI treatment...
  5. doi request reprint Interferon combination therapy for HIV/hepatitis C virus coinfection
    Aarthi Chary
    VA Palo Alto Health Care System, Palo Alto, CA, USA
    Immunotherapy 3:1087-102. 2011
    ..Understanding the basis of this population's poor response to interferon-based therapy is crucial to future exploration of new therapeutic options, immunotherapy and prognosis in HIV/HCV-coinfected population...
  6. pmc Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients
    Lauren E Kushner
    Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America
    PLoS ONE 8:e60387. 2013
    ..Few studies have evaluated HIV/HCV co-infection, and little longitudinal data exists describing a broader antiviral cytokine response...